Trial Profile

A Phase 2, Multicenter, Single Arm, Open Label, Non-Randomized Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fluorine-18 FAPI 74 (Primary)
Indications Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Liver cancer; Pancreatic cancer
Focus Diagnostic use
Acronyms 18F-FAPI-74 GI
Sponsors SOFIE

Most Recent Events

22 Jan 2026 Actual primary completion date changed from 1 Jul 2025 to 30 Jun 2025.
01 Oct 2025 Primary endpoint (Positive predictive value will be determined on a per-lesion basis for all lesions with tissue available for FAP analysis.) has been met, according to a SOFIE Biosciences media release.
01 Oct 2025 Results presented in a SOFIE Biosciences media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com